危重型新型冠状病毒肺炎的诊疗进展

doi:10.3969/j.issn.1006-7795.2020.03.001

摘要/Abstract

摘要： 新型冠状病毒肺炎（以下简称新冠肺炎）在世界范围内广泛传播，已经成为当前最严峻的全球性公共卫生事件。危重型新冠肺炎的救治是降低病死率的关键，也是当前临床面临的严峻挑战。本文通过对新冠肺炎病原学、流行病学特点、病理改变、发病机制、临床特征、临床救治方案进展的论述，为危重型新冠肺炎的诊治提供参考。

关键词: 新型冠状病毒肺炎, 危重型, 诊断, 治疗

Abstract: COVID-2019 has been widely spread around the world and has become the most severe current global public health event. The treatment of critical COVID-19 is the key to reduce the fatality rate and is also a severe clinical challenge for us. We discussed the etiology, epidemiological characteristics, pathological changes, pathogenesis, clinical characteristics and clinical treatment program of COVID-19, to provide reference for the diagnosis and treatment of critical COVID-19.

Key words: COVID-19, type of critical, diagnosis, treatment

中图分类号:

R563.1

刘景院, 郭贺冰, 李昂. 危重型新型冠状病毒肺炎的诊疗进展[J]. 首都医科大学学报, 2020, 41(3): 321-327.

Liu Jingyuan, Guo Hebing, Li Ang. Progress in diagnosis and treatment of critical COVID-19[J]. Journal of Capital Medical University, 2020, 41(3): 321-327.

参考文献

[1] WHO. Coronavirus disease (COVID-19) outbreak situation[EB/OL].(2020-04-15)[2020-04-15].https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
[2] WHO. Coronavirus disease 2019(COVID-19)[EB/OL]. (2020-04-15)[2020-04-15].https://www.who.int.
[3] Wu Z, Mcgoogan J M. Characteristics of and important lessons from the Coronavirus Disease 2019(COVID-19) outbreak in China[J]. JAMA, 2020, 323(13):1239-1242.
[4] Chih-Cheng L, Tzu-Ping S, Wen-Chien K, et al. Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) and coronavirus disease-2019(COVID-19):the epidemic and the challenges.[J]. Int J Antimicrob Agents, 2020, 55(3):1010-1016.
[5] Zhang Y, Holmes E C. A genomic perspective on the origin and emergence of SARS-CoV-2[J]. Cell,2020, 181(2):223-227.
[6] Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J]. Lancet,2020, 395(10224):565-574.
[7] WHO. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected:interim guidance, 13 March 2020[EB/OL]. (2020-03-13)[2020-04-15] https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected.
[8] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet,2020, 395(10223):497-506.
[9] Livingston E, Bucher K. Coronavirus Disease 2019(COVID-19) in Italy[J]. JAMA,2020,323(14):1335.
[10] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China:a retrospective cohort study[J]. Lancet,2020, 395(10229):1054-1062.
[11] Barnaby Edward Young M B, Sean Wei Xiang Ong M, Shirin Kalimuddin M, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore[J]. JAMA,2020, 323(3):2010-2020.
[12] Jason T P, Bhakti K P, Andrew M D,et al. Management of critically ill adults with COVID-19[EB/OL]. (2020-03-26)[2020-04-15]. https://doi:10.1001/jama.2020.4914.
[13] Wang L, He W, Yu X, et al. Coronavirus disease 2019 in elderly patients:characteristics and prognostic factors based on 4-week follow-up[J]. Infect,2020,80(6):1010-1016.
[14] Mcmichael T M, Currie D W, Clark S, et al. Epidemiology of COVID-19 in a long-term care facility in King County, Washington[J/OL]. N Engl J Med. (2020-03-27)[2020-04-15]. https://doi:10.1056/NEJMoa2005412.
[15] Graziano Onder M P, Giovanni Rezza M, Silvio Brusaferro M. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy[J]. JAMA,2020,23:2010-2020.
[16] 张婷,孙鹿希,冯瑞娥. 严重急性呼吸综合征与新型冠状病毒肺炎临床病理表现及对比分析[J]. 中华结核和呼吸杂志. (2020-04-03)[2020-04-15]. https://DOI:10.3760/cma.j.cn112147-20200311-00312.
[17] Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2[J/OL]. Gastroenterology,(2020-03-03)[2020-04-15]. https://doi:10.1053/j.gastro.2020.02.055.
[18] 国家卫生健康委办公厅.新型冠状病毒感染的肺炎诊疗方案(试行第七版)[EB/OL]. (2020-03-03)[2020-04-15]. https://DOI:10.19844/j.cnki.1672-397X.2020.04.001.
[19] Zou X, Chen K, Zou J, et al. The single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to Wuhan 2019-nCoV infection[J/OL]. Front Med.(2020-03-12)[2020-04-15]. https://doi:10.1007/s11684-020-0754-0.
[20] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China[J]. JAMA, 2020:1000-1001.
[21] Jin Y, Yang H, Ji W, et al. Virology, epidemiology, pathogenesis, and control of COVID-19[J]. Viruses,2020, 12(4):372.
[22] Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19[J/OL]. Pharmaceut Anal.(2020-03-5)[2020-04-15]. https://doi:10.1016/j.jpha.2020.03.001.
[23] Rodriguez-Morales A J, Cardona-Ospina J A, Gutiérrez-Ocampo E, et al. Clinical, laboratory and imaging features of COVID-19:a systematic review and meta-analysis[J]. Travel Med Infect Dis,2020:101623.
[24] Francois-Xavier Lescure M, Lila Bouadma M, Duc Nguyen M, et al. Clinical and virological data of the first cases of COVID-19 in Europe:a case series[J/OL]. Lancet Infect Dis. (2020-03-27)[2020-04-15]. https://doi:10.1016/S1473-3099(20)30200-0.
[25] 上海市新型冠状病毒病临床救治专家组. 上海市2019冠状病毒病综合救治专家共识[J/OL]. 中华传染病杂志. (2020-03-01)[2020-04-15]. https://DOI:10.3760/cma.j.issn.1000-6680.2020.0016.
[26] 倪勤,丁丞,李永涛,等. 中低剂量糖皮质激素对新型冠状病毒肺炎患者病毒清除的回顾性分析研究[J/OL]. 中华临床感染病杂志. (2020-02-28)[2020-04-15]. https://DOI:10.3760/cma.j.cn115673-20200225-00072.
[27] 中华医学会呼吸病学分会,中国医师协会呼吸医师分会. 新型冠状病毒肺炎防治专家意见[J/OL]. 中华结核和呼吸杂志. (2020-04-05)[2020-04-15]. https://DOI:10.3760/cma.j.cn112147-112147-20200321-00392.
[28] 刘清泉,夏文广,安长青,等. 中西医结合治疗新型冠状病毒肺炎作用的思考[J]. 中医杂志, 2020, 61(6):463-464.
[29] Wang Z, Chen X, Lu Y, et al. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment[J]. Biosci Trends,2020,14(1):64-68.
[30] Runfeng L, Yunlong H, Jicheng H, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)[J/OL]. Pharmacol Res. (2020-03-20)[2020-04-15]. https://doi:10.1016/j.phrs.2020.104761.
[31] Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19[J/OL]. Kidney Int. (2020-03-20)[2020-04-15]. https://doi:10.1016/j.kint.2020.03.005.
[32] Kochi A N,Tagliari A P,Forleo G B,et al. Giovanni Battista Forleo, Claudio Tondo. Cardiac and arrhythmic complications in patients with COVID-19[J]. J Cardiovasc Electrophysiol, 2020,(2020):1-6.
[33] Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China[J/OL]. JAMA Cardiol. (2020-03-25)[2020-04-15]. https://doi:10.1001/jamacardio.2020.0950.
[34] 靳英辉,蔡林,程真顺,等. 新型冠状病毒(2019-nCoV)感染的肺炎诊疗快速建议指南(标准版)[J]. 解放军医学杂志,2020, 45(1):1-20.